PRESS RELEASE published on 11/12/2025 at 07:30, 5 months 2 days ago Informations privilégiées / Autres communiqués ADOCIA dépose un brevet pour une nouvelle plateforme de peptides à action prolongée, AdoXLongTM, et fait avancer sa technologie BioChaperone® pour le traitement du diabète et de l'obésité Obésité Diabète ADOCIA Peptides Action Prolongée
PRESS RELEASE published on 11/12/2025 at 07:30, 5 months 2 days ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 5 months 24 days ago Franchissement de seuils chez ADOCIA Actions Franchissement De Seuils Bons De Souscription ADOCIA Vester Finance
BRIEF published on 10/21/2025 at 10:47, 5 months 24 days ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
PRESS RELEASE published on 10/21/2025 at 10:42, 5 months 24 days ago Franchissement de seuils Déclaration de franchissement de seuils par Vester Finance pour ADOCIA avec 889 555 actions, 4,86% du capital et 4,36% des droits de vote Déclaration Actions Franchissement De Seuils ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 5 months 30 days ago Résultats positifs pour l'insuline BioChaperone® Lispro en Phase 3 Essai Clinique Diabète De Type 1 ADOCIA BioChaperone® Tonghua Dongbao
BRIEF published on 10/15/2025 at 08:50, 5 months 30 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 5 months 30 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
PRESS RELEASE published on 10/15/2025 at 08:45, 5 months 30 days ago Informations privilégiées / Autres communiqués Adocia et Tonghua Dongbao annoncent des résultats positifs d'essai clinique de Phase 3 sur l'insuline BioChaperone® Lispro THDB0206 injection pour le Diabète de Type 1 en Chine Diabète De Type 1 ADOCIA Tonghua Dongbao Insuline BioChaperone Lispro
BRIEF published on 07/25/2025 at 08:50, 8 months 20 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
Published on 04/14/2026 at 10:55, 1 hour 38 minutes ago Waton Financial Marks One Year as a Listed Company with MOTA: A New Chapter in Human-AI Investment Collaboration
Published on 04/14/2026 at 09:05, 3 hours 28 minutes ago BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
Published on 04/14/2026 at 09:01, 3 hours 32 minutes ago Star Copper Fully Funded 15,000 Metre Drill Program Targets Maiden Resource in 2026
Published on 04/13/2026 at 23:15, 13 hours 18 minutes ago Relevant Gold Completes Strategic Financing; Embarks on Largest Drilling Program in Company History
Published on 04/13/2026 at 23:00, 13 hours 33 minutes ago Sterling Metals Announces Sale Of Sail Pond Project
Published on 04/14/2026 at 11:00, 1 hour 33 minutes ago CATHAROS launches: Germany’s local marketplace for medical cannabis
Published on 04/14/2026 at 10:30, 2 hours 3 minutes ago Baucor Boosts European Operations with Strategic Product Expansion
Published on 04/14/2026 at 10:00, 2 hours 33 minutes ago ARTCLINE achieves milestone in septic shock: Patient recruitment for the ReActIF-ICE study successfully completed
Published on 04/14/2026 at 08:30, 4 hours 3 minutes ago ALPOU - Groupe POULAILLON - Projet offre publique d'achat obligatoire
Published on 04/13/2026 at 19:14, 17 hours 18 minutes ago ALTAREA - Déclaration d’opérations sur actions propres
Published on 04/13/2026 at 18:15, 18 hours 18 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2026
Published on 04/13/2026 at 18:15, 18 hours 18 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2026
Published on 04/13/2026 at 18:09, 18 hours 24 minutes ago Infotel : Cessation et mise en œuvre d’un nouveau contrat de liquidité avec Invest Securities.
